Type 1 diabetes is an autoimmune disorder that affects nearly 347 million people worldwide.

The autoimmune disorder is characterised by the destruction of insulin-producing beta cells in the pancreas by the patient’s immune system. Because insulin regulates the metabolism of glucose, its absence results in dangerously elevated glucose levels in the blood.

Patients are dependent on insulin injections to regulate their blood glucose level, which must be constantly monitored throughout the day to avoid hypo or hyperglycemia. Even with careful management, Type 1 diabetes patients face the constant risk of the disease’s serious side effects, which include kidney failure, blindness, nerve damage, heart attack, stroke, and pregnancy complications.

Noble Life Sciences has optimised a streptozotocin (STZ) induced rat model of diabetes. This is the model of choice for preclinical development of therapeutic agents for diabetes.